Sponsor or institution

Clinical trials and research at Takeda

• 78Clinical trials
• 54Countries

Newest trials

All recruiting trials (78)

• Rusfertide in Japanese adults with polycythemia vera

  This study tests rusfertide in Japanese adults with polycythemia vera to see if it helps keep hematocrit under control and reduce the need for blood removal.

  Recruiting at 8 sites Phase 2 Takeda · Nagoya, Aichi-ken and 8 other locations · NCT07648030

• Long-term test of TAK-360 in people with narcolepsy or idiopathic hypersomnia

  This study tests TAK-360 over an extended period to see if it is tolerable for people with narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia who completed an earlier TAK-360 trial.

  Recruiting at 33 sites Phase 2/3 Takeda · Chula Vista, California and 32 other locations · NCT07646678

• TAK-360 in adults with narcolepsy Type 1 with cataplexy

  This study tests TAK-360 versus placebo in adults with narcolepsy Type 1 to see if it is safe and tolerable.

  Recruiting at 9 sites Phase 2 Takeda · Redwood City, California and 17 other locations · NCT07633301

• Fruquintinib treatment in adults with metastatic colorectal cancer in Poland

  This study looks at whether taking fruquintinib by mouth after prior therapies helps adults with metastatic colorectal cancer in Poland live longer before the cancer progresses and overall survival, while also considering quality of life.

  Recruiting at 3 sites Takeda · Poznan, Greater Poland Voivodeship and 9 other locations · NCT07623174

• Elritercept vs. placebo for adults with myelofibrosis and anemia on ruxolitinib

  This study tests whether elritercept can improve anemia in adults with myelofibrosis who are taking ruxolitinib, compared with placebo.

  Recruiting at 11 sites Phase 3 Takeda · Gilbert, Arizona and 213 other locations · NCT07623161

• Mezagitamab for adults with late antibody-mediated rejection after kidney transplant

  Mezagitamab is being tested to see if it is safe and helps kidney transplant patients with late antibody-mediated rejection, compared with a placebo.

  Recruiting at 4 sites Phase 2 Takeda · Los Angeles, California and 34 other locations · NCT07613359

• Takhzyro use in teenagers and adults with hereditary angioedema in South Korea

  This study looks at how safe and useful Takhzyro is when used in real-world care for teenagers and adults with hereditary angioedema in South Korea.

  Recruiting at 3 sites Takeda · Suwon, Gyeonggi-do and 2 other locations · NCT07445087

• TAK-505 treatment for adults with advanced solid tumors

  This trial will test TAK-505, an experimental drug, in adults with locally advanced or metastatic solid tumors (such as stomach, colorectal, non-small cell lung, and head and neck cancers) who have limited standard treatment options.

  Recruiting at 13 sites Phase 1/2 Takeda · Orange, California and 14 other locations · NCT07436728

• cTTP patients treated with recombinant ADAMTS13: what happened after the early access program

  This study looks at people with congenital TTP who received recombinant ADAMTS13 to see how treatment changes their health before and after use.

  Recruiting Takeda · Cologne, North Rhine-Westphalia and 7 other locations · NCT07429942

• Elritercept versus epoetin alfa for transfusion-dependent anemia in lower-risk MDS

  This study tests whether elritercept can reduce the need for red blood cell transfusions and improve fatigue compared with epoetin alfa in adults with very low-, low-, or intermediate-risk myelodysplastic syndromes who need regular transfusions.

  Recruiting at 103 sites Phase 3 Takeda · Gilbert, Arizona and 165 other locations · NCT07422480

• Vonicog alfa (rVWF) use in children with von Willebrand disease

  This observational program will see how vonicog alfa (rVWF) works and whether it causes side effects in children with von Willebrand disease in Japan.

  Recruiting Takeda · Tokyo, Tokyo · NCT07404644

• Zasocitinib (TAK-279) in adults with active Crohn’s disease

  This study tests zasocitinib in adults with Crohn’s disease to see if it can reveal how the drug works in the gut and whether it is safe.

  Recruiting Phase 2 Takeda · Oxford · NCT07403968

• TAK-755 to treat acute ischemic stroke in adults

  This will test a single dose of TAK-755 versus placebo to see if it is safe and helps adults who had an acute ischemic stroke within 24 hours.

  Recruiting at 13 sites Phase 2 Takeda · Scottsdale, Arizona and 59 other locations · NCT07392450

• Adzynma in people with congenital TTP: a look at safety and antibody risk

  This study checks whether people with congenital TTP who have already received Adzynma develop neutralizing antibodies against Adzynma within six months of starting treatment.

  Recruiting at 6 sites Takeda · Vienna and 6 other locations · NCT07353099

• TAK-226 for anemia in lower-risk MDS in Japanese patients

  This trial tests TAK-226 to see if it improves transfusion-dependent anemia in Japanese adults with lower-risk myelodysplastic syndromes.

  Recruiting at 11 sites Phase 2 Takeda · Tokyo, Bunkyo-ku and 20 other locations · NCT07319845

• Teduglutide treatment for Chinese children and teenagers with short bowel syndrome

  This test will see if teduglutide helps Chinese children and teenagers with short bowel syndrome reduce how much intravenous nutrition they need.

  Recruiting Takeda · Guangzhou, Guangdong and 3 other locations · NCT07319832

• Maralixibat (Livmarli) use in Alagille syndrome and PFIC — Japanese database analysis

  This project will look at Japanese patients with Alagille syndrome or PFIC who received maralixibat (Livmarli) to see if taking the drug is linked to liver problems.

  Recruiting Takeda · Tokyo, Tokyo · NCT07293897

• C1-Inhibitor Function Test to Diagnose HAE in Algeria

  A test that measures C1-inhibitor function is being tried to see if it can accurately diagnose hereditary angioedema in patients in Algeria.

  Recruiting Takeda · Algiers · NCT07293364

• Continued daily zasocitinib treatment for adults with psoriatic arthritis

  This extension will try daily zasocitinib in adults with psoriatic arthritis who completed a year of earlier treatment to see how well it works and how safe it is over about two years.

  Recruiting at 78 sites Phase 3 Takeda · Tucson, Arizona and 77 other locations · NCT07286058

• Long-term zasocitinib treatment for children and teenagers with plaque psoriasis

  This long-term study will see if the medicine zasocitinib is safe and helps children and teenagers (ages 4 to under 18) with moderate-to-severe plaque psoriasis.

  Recruiting at 37 sites Phase 3 Takeda · Chula Vista, California and 38 other locations · NCT07250802

• TAK-781 treatment in healthy adults and people with non-cirrhotic primary sclerosing cholangitis

  This study will test whether TAK-781 is safe and tolerable in healthy adults and in people with non-cirrhotic primary sclerosing cholangitis while measuring how the body handles and responds to the drug.

  Recruiting Phase 1 Takeda · Salt Lake City, Utah · NCT07229911

• IBI363 versus docetaxel for advanced squamous non-small cell lung cancer after standard treatments stopped working

  This trial tests whether IBI363 works better than the chemotherapy docetaxel for adults with advanced squamous non-small cell lung cancer whose platinum chemotherapy and PD‑1/PD‑L1 immunotherapy have stopped working.

  Recruiting at 37 sites Phase 3 Takeda · Jonesboro, Arkansas and 49 other locations · NCT07217301

• TAK-188 for adults with advanced or metastatic solid tumors

  This trial will test whether TAK-188, a drug that targets CCR8 to remove immune-suppressing cells in tumors, helps adults with advanced or metastatic solid tumors whose cancer has not improved after prior treatments.

  Recruiting at 15 sites Phase 1/2 Takeda · Santa Monica, California and 14 other locations · NCT07205718

• Vortioxetine for Japanese teens (12–17) with major depressive disorder

  This study will test if daily vortioxetine (10 mg or 20 mg) helps reduce depression symptoms and is safe compared with a placebo in Japanese teenagers aged 12 to 17.

  Recruiting at 30 sites Phase 3 Takeda · Nagoya, Aichi-ken and 29 other locations · NCT07204314

• Agalsidase alfa (Replagal) enzyme replacement for Chinese children and adults with Fabry disease

  This project will test whether agalsidase alfa (Replagal) helps heart and kidney health in Chinese children and adults with Fabry disease.

  Recruiting at 8 sites Takeda · Hefei, Anhui and 17 other locations · NCT07187440

• VONVENDI treatment for adults in China with von Willebrand disease

  We will test whether VONVENDI is safe and helps control bleeding in adult Chinese patients with severe von Willebrand disease, sometimes given with ADVATE if their factor VIII is low.

  Recruiting at 7 sites Phase 3 Takeda · Beijing and 6 other locations · NCT07129343

• Monitoring Fruzaqla treatment in adults with metastatic colorectal cancer in South Korea

  This project will track side effects, including serious ones, in adults in South Korea who are being treated with Fruzaqla (fruquintinib) for metastatic colorectal cancer.

  Recruiting Takeda · Seoul · NCT07035886

• Gammagard Liquid (10% immune globulin) to prevent infections in adults with multiple myeloma

  This will try regular Gammagard Liquid (10% immune globulin) infusions to prevent infections in adults with multiple myeloma who are receiving BCMA×CD3 bispecific antibody therapy.

  Recruiting at 65 sites Phase 3 Takeda · Mobile, Alabama and 64 other locations · NCT06980480

• Mezagitamab for adults with IgA nephropathy

  This trial will test if mezagitamab can reduce protein in the urine of adults with primary IgA nephropathy.

  Recruiting at 186 sites Phase 3 Takeda · Birmingham, Alabama and 185 other locations · NCT06963827

• Evaluating TAK-360 for adults with Narcolepsy Type 2

  This study is testing a new medication called TAK-360 to see if it can help adults with Narcolepsy Type 2 stay awake during the day.

  Recruiting at 44 sites Phase 2 Takeda · Auburn, Alabama and 51 other locations · NCT06952699

• Follow-up mezagitamab treatment for adults with chronic primary immune thrombocytopenia

  This follow-up will try giving mezagitamab longer-term to adults with chronic primary ITP who completed earlier mezagitamab studies to see if it stays safe, is tolerated, and helps maintain platelet responses.

  Recruiting at 55 sites Phase 3 Takeda · Hot Springs, Arkansas and 117 other locations · NCT06948318

• Effectiveness of Dengue Vaccine in Children and Adolescents

  This study is testing how well a new dengue vaccine works to keep children and teens in Southeast Asia out of the hospital due to dengue fever.

  Recruiting at 3 sites Takeda · Banjarmasin, South Kalimantan and 6 other locations · NCT06843226

• Combining brentuximab vedotin with standard chemotherapy for Hodgkin lymphoma in adults

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help adults with untreated Hodgkin lymphoma feel better and improve their treatment results.

  Recruiting at 5 sites Phase 4 Takeda · Vijayawada, Andhra Pradesh and 10 other locations · NCT06831370

• Evaluating TAK-360 for daytime sleepiness in adults with Idiopathic Hypersomnia

  This study is testing a new medication called TAK-360 to see if it can help adults with Idiopathic Hypersomnia feel less sleepy during the day.

  Recruiting at 28 sites Phase 2 Takeda · Redwood City, California and 28 other locations · NCT06812078

• Testing TAK-411 for treating CIDP in adults

  This study is testing a new treatment called TAK-411 to see if it can help adults with CIDP feel better and improve their physical abilities.

  Recruiting at 22 sites Phase 2 Takeda · La Jolla, California and 21 other locations · NCT06798012

• Continued TAK-279 treatment in adults with ulcerative colitis or Crohn's disease

  Adults with moderate to severe ulcerative colitis or Crohn's disease who responded to earlier TAK-279 can continue TAK-279 for up to two years to see if it remains safe and lowers bowel inflammation and symptoms.

  Recruiting at 16 sites Phase 2 Takeda · Glen Burnie, Maryland and 15 other locations · NCT06764615

• Comparing TAK-881 and HYQVIA as maintenance treatment for adults with CIDP

  This test will see if TAK-881 given under the skin works like HYQVIA for adults with CIDP who are already on IgG therapy.

  Recruiting at 16 sites Phase 3 Takeda · Scottsdale, Arizona and 51 other locations · NCT06747351

• Mezagitamab treatment for adults with chronic immune thrombocytopenia

  This study is testing if a new treatment called mezagitamab can help adults with chronic immune thrombocytopenia keep their platelet counts stable compared to a placebo.

  Recruiting at 69 sites Phase 3 Takeda · Hot Springs, Arkansas and 123 other locations · NCT06722235

• Testing Zasocitinib for Psoriatic Arthritis in Adults

  This study is testing a new medication called zasocitinib to see if it can help adults with active psoriatic arthritis who haven't tried biologic treatments before.

  Recruiting at 177 sites Phase 3 Takeda · Chandler, Arizona and 187 other locations · NCT06671483

• Two-dose tetravalent dengue vaccine for infants and toddlers

  This will test whether two doses of a tetravalent dengue vaccine given three months apart are safe and help children aged 6 to under 21 months develop protective immune responses.

  Recruiting Phase 3 Takeda · Barranquilla, Atlántico and 3 other locations · NCT06665035

• Evaluating a new treatment for congenital protein C deficiency

  This study is testing a new treatment using a special protein to see if it helps people with congenital protein C deficiency feel better and stay safe over two years.

  Recruiting Takeda · Tokyo, Tokyo · NCT06590974

• Treatment of Ulcerative Colitis and Crohn's Disease with Vedolizumab

  This study is testing if a new medication called Vedolizumab can help adults with Ulcerative Colitis or Crohn's Disease feel better and stay symptom-free over a year.

  Recruiting at 78 sites Phase 4 Takeda · Birmingham, Alabama and 100 other locations · NCT06581328

• Survey of Maribavir tablets for treating Cytomegalovirus infection

  This study is testing if Maribavir tablets can help people with Cytomegalovirus infection who haven't responded to other treatments, especially those who have had an organ transplant.

  Recruiting Takeda · Tokyo, Tokyo · NCT06577363

• Evaluating the safety of a 20% Immune Globulin solution in patients with primary immunodeficiency

  This study is trying to see if a 20% immune globulin solution is safe for people with primary immunodeficiency diseases by looking at past patient data from Japan.

  Recruiting Takeda · Tokyo, Tokyo · NCT06565078

• Evaluating fruquintinib's safety in minority groups with advanced colorectal cancer

  This study is testing if fruquintinib is safe for Black and Hispanic adults with advanced colorectal cancer who have already had treatment.

  Recruiting at 32 sites Phase 4 Takeda · Birmingham, Alabama and 44 other locations · NCT06562543

• Evaluating LIVTENCITY for treating CMV infection in transplant patients in South Korea

  This study is testing if LIVTENCITY can safely and effectively treat cytomegalovirus (CMV) infection in adults who have had a transplant and haven't had success with other treatments.

  Recruiting Takeda · Seoul · NCT06555432

• OBIZUR treatment for adults with acquired hemophilia A in South Korea

  This project will test how safe OBIZUR is and whether it helps control bleeding in adults in South Korea who have acquired hemophilia A.

  Recruiting at 4 sites Takeda · Seoul and 3 other locations · NCT06550882

• Understanding the use of HyQvia in adults with CIDP

  This study looks at why adults with CIDP choose HyQvia for treatment and how it affects their satisfaction, daily life, and work productivity.

  Recruiting at 11 sites Takeda · Rancho Mirage, California and 14 other locations · NCT06538064

• Understanding liver problems in adults with Alpha-1 Antitrypsin Deficiency

  This study looks at how liver problems develop over time in adults with Alpha-1 Antitrypsin Deficiency to better understand their health and improve treatment options.

  Recruiting at 8 sites Takeda · Gainesville, Florida and 7 other locations · NCT06512454

• Evaluating Elritercept for Anemia in Adults with Myelodysplastic Syndromes

  This study is testing if a new treatment called elritercept can help adults with myelodysplastic syndromes who have anemia feel better and need fewer blood transfusions.

  Recruiting at 163 sites Phase 3 Takeda · Duarte, California and 181 other locations · NCT06499285

• Survey of a treatment for Acquired Hemophilia A

  This study is trying out a new injection treatment for people with Acquired Hemophilia A in Japan to see if it helps reduce bleeding and what side effects it might have.

  Recruiting Takeda · Tokyo, Tokyo · NCT06461533

• Evaluating the safety and effectiveness of vedolizumab in children and teenagers with chronic pouchitis

  This study is testing if a medication called vedolizumab can help children and teenagers with chronic pouchitis feel better and stay healthy after bowel surgery.

  Recruiting at 14 sites Phase 3 Takeda · Leuven, Vlaams-Brabant and 13 other locations · NCT06443502

• Survey of a treatment for congenital thrombotic thrombocytopenic purpura

  This study is testing a new treatment called recombinant ADAMTS13 to see if it helps people with congenital thrombotic thrombocytopenic purpura feel better and stay healthy over 18 months.

  Recruiting Takeda · Tokyo, Tokyo · NCT06441578

• Long-term vedolizumab treatment for children and teenagers with ulcerative colitis or Crohn's disease

  This extension tests whether continuing subcutaneous vedolizumab is safe and helps children and teenagers with moderate to severe ulcerative colitis or Crohn's disease stay well.

  Recruiting at 12 sites Phase 3 Takeda · Phoenix, Arizona and 46 other locations · NCT06405087

• Maribavir for CMV in adults with kidney failure after transplantation

  This project will see if maribavir is safe for adults with severe kidney failure (including people on dialysis) who develop CMV after a transplant by reviewing existing medical records.

  Recruiting at 9 sites Takeda · Anderlecht, Brussels Capital and 24 other locations · NCT06243731

• Evaluating TAK-279 for reducing bowel inflammation in Crohn's disease

  This study is testing if a new medication called TAK-279 can help reduce bowel inflammation in people with moderate to severe Crohn's disease.

  Recruiting at 189 sites Phase 2 Takeda · Murrieta, California and 200 other locations · NCT06233461

• Combining vedolizumab and upadacitinib for treating Crohn's Disease

  This study is testing if combining two medications, vedolizumab and upadacitinib, can help adults with moderate to severe Crohn's Disease feel better compared to using vedolizumab alone.

  Recruiting at 8 sites Phase 3 Takeda · La Jolla, California and 137 other locations · NCT06227910

• Investigating the safety and effects of Fazirsiran for liver disease caused by Alpha-1 Antitrypsin Deficiency

  This study is testing a new medication called Fazirsiran to see if it can safely help people with liver disease caused by Alpha-1 Antitrypsin Deficiency by reducing a harmful protein.

  Recruiting at 40 sites Phase 3 Takeda · Phoenix, Arizona and 40 other locations · NCT06165341

• Vedolizumab treatment for children and teenagers with ulcerative colitis or Crohn's disease

  This study is testing how well the drug vedolizumab works for children and teenagers with ulcerative colitis or Crohn's disease when given through injections after an initial dose through an IV.

  Recruiting at 26 sites Phase 3 Takeda · Phoenix, Arizona and 53 other locations · NCT06100289

• Using HyQvia for treating adults with multiple myeloma and secondary immunodeficiency

  This study is testing how well HyQvia works for adults with multiple myeloma and a weakened immune system by looking at their treatment experiences over a year.

  Recruiting at 14 sites Takeda · Córdoba and 26 other locations · NCT05879757

• Evaluating Vedolizumab for treating moderate to severe Crohn's Disease in adults

  This study is testing if an intravenous medication called vedolizumab can help adults in China with moderate to severe Crohn's Disease feel better over 58 weeks.

  Recruiting at 33 sites Phase 3 Takeda · Hefei, Anhui and 42 other locations · NCT05837897

• Evaluating TAK-861 for treating narcolepsy type 1

  This study is testing a new medication called TAK-861 to see if it can help people with narcolepsy type 1 feel less sleepy during the day and reduce their sudden muscle weakness.

  Recruiting at 52 sites Phase 2/3 Takeda · Birmingham, Alabama and 51 other locations · NCT05816382

• Evaluating the safety and effectiveness of fazirsiran for liver disease caused by an abnormal protein.

  This study is testing if a new drug called fazirsiran can help reduce liver scarring in people with Alpha-1 Antitrypsin Deficiency.

  Recruiting at 81 sites Phase 3 Takeda · Birmingham, Alabama and 88 other locations · NCT05677971

• Evaluating vonicog alfa for children with severe Von Willebrand Disease

  This study is testing a new treatment called vonicog alfa to see if it can help children with severe Von Willebrand Disease manage their bleeding better.

  Recruiting at 19 sites Phase 3 Takeda · Birmingham, Alabama and 22 other locations · NCT05582993

• Survey of Brentuximab Vedotin for treating pediatric Hodgkin Lymphoma

  This study looks at how well Brentuximab Vedotin works with standard treatment for kids with Hodgkin lymphoma and checks for any side effects they might have.

  Recruiting Takeda · Tokyo, Tokyo · NCT05481437

• Vedolizumab treatment for children with ulcerative colitis or Crohn's disease

  This study is testing how safe the medication vedolizumab is for children with ulcerative colitis or Crohn's disease who have already tried it before.

  Recruiting at 44 sites Phase 3 Takeda · Mobile, Alabama and 97 other locations · NCT05442567

• Observing the effects of vedolizumab in adults with ulcerative colitis or Crohn's disease in South Korea

  This study is looking at how well the medication vedolizumab works for adults in South Korea with moderate to severe ulcerative colitis or Crohn's disease who haven't had success with other treatments.

  Recruiting Takeda · Goyang-si, Gyeonggi-do · NCT05428345

• Maribavir treatment for CMV infection in children and adolescents after stem cell or organ transplant

  This study tests whether maribavir is safe and works to treat CMV infection in children and teenagers who have had a stem cell or solid organ transplant.

  Recruiting at 53 sites Phase 3 Takeda · Wilmington, Delaware and 52 other locations · NCT05319353

• Using TAK-330 to reverse blood thinning effects for urgent surgeries

  This study is testing if a new drug called TAK-330 can work better than a standard treatment to reverse blood thinning effects for adults who need urgent surgery.

  Recruiting at 61 sites Phase 3 Takeda · Arkansas City, Arkansas and 63 other locations · NCT05156983

• Survey of Darvadstrocel for treating Crohn's disease

  This study looks at how well Darvadstrocel injections work for people with Crohn's disease and complicated anal fistulas in Japan, while also keeping track of any side effects over three years.

  Recruiting Takeda · Tokyo, Tokyo · NCT05113095

• Survey of Brigatinib for treating non-small cell lung cancer

  This study looks at how safe Brigatinib is for Japanese patients with non-small cell lung cancer while they take the medication as part of their regular treatment.

  Recruiting Takeda · Tokyo · NCT05100069

• Evaluating Brentuximab Vedotin for Adults with Hodgkin's Lymphoma

  This study is testing how well Brentuximab Vedotin works and how safe it is for adults with Hodgkin's Lymphoma who are getting or preparing for a stem cell transplant.

  Recruiting at 13 sites Takeda · Wroclaw, Dolnoslskie and 12 other locations · NCT05100056

• Replagal for children and adults with Fabry disease in India

  The study will try giving Replagal every two weeks for about a year to children and adults in India who have Fabry disease to learn more about its safety.

  Recruiting at 2 sites Phase 4 Takeda · Kolkata and 2 other locations · NCT05067868

• Evaluating KER-050 for treating Myelofibrosis

  This study is testing a new treatment called KER-050 to see if it can help people with Myelofibrosis improve their blood cell counts and overall quality of life, both on its own and with another medication.

  Recruiting at 39 sites Phase 2 Takeda · Concord, New South Wales and 45 other locations · NCT05037760

• Measuring prucalopride levels in breast milk of breastfeeding women with constipation

  This study is testing how much of the constipation medication prucalopride is found in the breast milk of breastfeeding women to see if it affects their babies.

  Recruiting Takeda · La Jolla, California · NCT04838522

• Treatment of moderate to severe Crohn's disease in children and teenagers with vedolizumab

  This study is testing if a new medication called vedolizumab can help children and teenagers with moderate to severe Crohn's disease feel better and reduce inflammation in their digestive system.

  Recruiting at 29 sites Phase 3 Takeda · Phoenix, Arizona and 95 other locations · NCT04779320

• Treatment of anemia in patients with myelodysplastic syndromes using KER-050

  This study tests if a new treatment called KER-050 can help people with myelodysplastic syndromes who have anemia by boosting their red blood cell and platelet production.

  Recruiting at 35 sites Phase 2 Takeda · Hot Springs, Arkansas and 52 other locations · NCT04419649

• Registry for patients with Gaucher Disease

  This study is collecting information from people with Gaucher Disease to see how well different treatments work and to learn more about the disease over time.

  Recruiting Takeda · Lexington, Massachusetts · NCT03291223

Quick answers

How many clinical trials run by Takeda are recruiting right now?

78, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 54 countries. The most sites are in United States (42 trials), Japan (36 trials), Spain (30 trials), Italy (27 trials), Poland (26 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 27, Phase 2: 13, Phase 4: 4, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →